Objective: The Freedom SOLO aortic valve is a bovine pericardial stentless valve, which requires only one suture line. The aim of our singlecentre retrospective study was to assess postoperative and intermediate-term haemodynamic results of the first 100 consecutively implanted valves. Methods: One hundred patients (39 male and 61 female) underwent aortic valve replacement with a Freedom SOLO from November 2006 to January 2008. Their clinical, operative, platelet levels, echocardiography and follow-up data were prospectively recorded. All but two patients were available for follow-up (98% completeness), which averaged 12.6 AE 5.06 months. Results: Associated procedures were performed in 38 patients (38%): 27 coronary artery bypass grafting (CABG), 11 mitral valve replacement, 11 septal myectomy and one ablation for atrial fibrillation. The mean age at the time of surgery was 77.2 AE 6.43 years. The mean European System for Cardiac Operative Risk Evaluation (EuroSCORE) was 8.05 AE 2.07. Mean cross-clamp time of isolated valve replacements was 51.27 AE 4.7 min and 63.18 AE 21.7 min with associated procedures. The mean implanted valve size was 23.5 AE 1.9 mm. One patient was re-operated for bleeding, two for pericardial effusion and 39 were transfused. The overall hospital mortality was 3%. One patient died suddenly postoperatively, and a second due to a fatal atrio-ventricular block. A third patient died following a subdural bleed. Three patients required a pacemaker before hospital discharge. The overall patient survival was 97 AE 2.26% at 1 year. Echocardiographic results preoperative, 8 days postoperative and 12 months after surgery showed mean transvalvular gradients of 50.6 AE 15.3, 15.6 AE 5.2 and 11.5 AE 3.8 mm Hg, respectively, and mean left ventricular ejection fractions of 37.9 AE 10.2%, 44 AE 15.2% and 53.6 AE 10.4%. Effective orifice area index for valve sizes 19, 21, 23, 25 and 27 were 0.91 AE 0.08, 0.97 AE 0.1, 1.08 AE 0.07, 1.53 AE 0.12 and 1.57 AE 0.1 cm 2 m À2 , respectively. There were three early non-structural dysfunctions (grade 1) of regurgitation, which remained stable at 12 months. Conclusions: Freedom SOLO valve has very good early-and intermediate-term results. Short implantation times and its haemodynamic performances, particularly in small diameters, allow us to use it by first intention in older and often sicker patients. These results must be confirmed by long-term outcomes. #
Introduction
The Freedom SOLO (FS) aortic valve ( Fig. 1) is an evolution of the Pericarbon Freedom, which required only one suture line [1] . As the latter, it is a stentless pericardial valve prosthesis made of two sheets of pericardium with no fabric reinforcement. Like stentless bioprostheses, it was designed to provide improved transvalvular gradients and increased orifice areas compared with the other generations' stented pericardial bioprostheses and particularly in patients with reduced ventricular function [2, 3] . This valve, still recent but increasingly used, has not yet been the subject of a published haemodynamic study on a wide range of patients. This singlecentre study reports our experience with the FS pericardial valve to assess early and intermediate-term haemodynamics results of the first 100 consecutive implanted valves.
Materials and methods

Study population
From November 2006 to January 2008, 100 patients underwent 100 aortic valve replacements (AVRs) with the implantation of FS pericardial valves (Sorin Group, Saluggia, Italy). The indications for AVR were aortic stenosis and/or regurgitation. Implantation of the FS valve was performed by only two experienced surgeons of the Department of Cardiac Surgery of the University of Bordeaux. Demographic and clinical preoperative data of the study population are listed in Table 1 . Where eligible for an FS valve implantation, all patients were operated by our team where a bioprosthesis was indicated (age older than 65 years, contraindication to oral anticoagulant therapy and request for a biologic valve by the patient and surgeon's preferences) and showed no exclusion criteria. These exclusion criteria included aortic annulus too heavily calcified, evident coronary ostia and Valsalva sinuses asymmetry, major dilatation of the sinotubular junction and congenital malformation (bicuspid aortic valve was a relative exclusion criteria).
Regarding the atrial fibrillation, our policy was not very aggressive and we treat essentially the atrial fibrillation known to be recent and/or paroxysmal.
Surgical intervention
Surgical intervention was performed during normothermia (35 8C) in all patients. Myocardial protection was obtained by using intermitted antegrade warm blood cardioplegia. FS valves were implanted with a continuous supra-annular suture line technique using three 4/0 prolene monofilament running sutures starting at the base of each sinus Valsalva and proceeding to the top of the commisures (Fig. 2) . They are treated with glutaraldehyde (GA) and are detoxified using homocysteic acid (HA), following a Sorin Group proprietary process, eliminated the need for rinsing before implantation.
Valve sizes 19, 21, 23, 25 and 27 were implanted in three (3%), 21 (21%), 37 (37%), 28 (28%) and 11 (11%) patients, respectively. The mean implanted valve size was 23.5 AE 1.95 mm. Approximately one-third, or 38 patients, underwent concomitant interventions including myocardial revascularisation (coronary artery bypass grafting (CABG), n = 27), mitral valve replacement (MVR, n = 11), septal myectomy (n = 11) and one patient (1%) underwent surgical ablation for atrial fibrillation. Operative data characteristics of the study population are listed in Table 2 .
Indications for AVR were as follows: calcific aortic stenosis in 78 (78%), aortic regurgitation in 14 (14%), congenital bicuspid valve in five (5%), endocarditis in two (2%) and prosthesis malfunction in one (1%) patients. Prior cardiac operations had been performed in three patients (3%): one AVR, one MVR and one patient had undergone myocardial revascularisation. 
Postoperative management
After implantation, oral anticoagulant therapy is not the routine for bioprostheses at our institution. All patients received subcutaneous weight-adapted high-molecularweight heparin until discharge from the hospital. Permanent anticoagulant therapy was begun in nine (9%) patients for atrial fibrillation and in two (2%) patients for mitral mechanical valve. Regarding these two patients, one patient had previously undergone mitral surgery. In the other case, the bioprosthesis choice in aortic position had been made regarding the two small aortic and mitral annuli. The stentless valve was supposed to provide less shear stress at the trigone when another valve was already in the mitral position. Chronic anti-platelet therapy with Acetylsalicylate de lysine, 75 or 160 mg daily was instituted in an additional 89 patients (89%).
Monitoring of the platelet counts
In 2008, Yerebakan et al. [4] reported severe thrombocytopaenia with 20 patients who received the FS aortic stentless pericardial bioprosthesis within the first days after implantation. We wanted to observe our own results. For further retrospective comparison, data of the 62 SOLO patients (SF group) with AVR isolated were retrospectively matched with 62 stented bioprosthesis patients (SP group), who were operated during the same period, by the same team. There was no difference in the strategy of the operation or in the postoperative management between the two groups, except that in our team, the stented valves were implanted by multiple U-sutures. Thereby, the two groups differed at the mean cross-clamp time 58.6 AE 5.3 min (P < 0.04) for the stented bioprosthesis group. Platelet levels were measured preoperatively, at hours 8, 24 and 48 and postoperatively at days 5, 8 and 10. The blood samples were analysed in our haematological laboratory. Heparininduced thrombocytopaenia (HIT) was suspected in two patients in the FS group and one patient in the SP group because of the reduction in platelet count. In the three cases, Danaparoid was begun with the same time of cessation of heparin.
Follow-up
Patients were followed up on a yearly basis at our outpatient clinic or by their physician. Duration of clinical follow-up averaged 12.6 AE 5 months (range, 2-20 months) and it was 98% complete, with two patients lost during follow-up. For purposes of this study, we studied the last echocardiography performed for all the 95 survivors not lost sight of. The mean echocardiographic follow-up time was 12.4 AE 4.9 months (range, 2.5-18 months).
Echocardiograms from outside laboratories were sent to us by the patients' referring cardiologists. Mean transvalvular pressure gradients were derived by using the modified Bernoulli equation and the effective orifice area were calculated with the continuity equation.
Definitions and data analysis
Valve-related complications are reported according to the 1996 Guidelines of the Ad Hoc Liaison Committee of The Society of Thoracic Surgeons and The American Association of Thoracic Surgery and the 2008 guidelines of the European Association for Cardio-Thoracic Surgery (EACTS) [5, 6] . These include overall valve-related morbidity, thrombo-embolism, anticoagulant-related haemorrhage, endocarditis, nonstructural valve dysfunction (perivalvular leak, clinically significant haemolysis), structural valve deterioration (stenosis or insufficiency due to any intrinsic degenerative change) and re-operation (repair or replacement of implanted prosthesis). The demographic, haemodynamic data and platelet levels are reported as mean AE standard deviation. Statistical analysis for platelet levels was performed using Student's dependent t-tests. A Pvalue < 0.05 was considered to be statistically significant.
Results
Operative mortality and morbidity, functional status, and survival rates
There were three early deaths, for an overall 30-day mortality rate of 3%. Early mortality rates were 18.1% (n = 2) after AVR and myectomy, 1.6% (n = 1) after AVR isolated. Survivors saw their symptoms significantly improved. At last follow-up, 85% of patients were the New York Heart Association (NYHA) class I or II. No late deaths were recorded. Causes of early death are summarised below. One death was valve related: the patient, anticoagulated for atrial fibrillation, died following a subdural bleed. The other two early deaths were due to other cardiac-related causes: one patient died suddenly postoperatively, and a second due to a fatal atrio-ventricular block. Three patients had a complete atrio-ventricular block and needed permanent pacemaker implantation before hospital discharge. Thirtynine patients (39%) have required homologous blood transfusions and including three patients who underwent re-intervention for postoperative bleeding or for pericardial effusion. The actuarial survival curve, which includes early deaths, is depicted in Fig. 3 . The survival rate at 18 months after an AVR was 97%.
Thrombo-embolism
There were three minor thrombo-embolic episodes with complete recovery -two events in the nursing home and the other event 4 months after hospital discharge. The first two patients in a nursing home were both on anticoagulants for sustained episodes of atrial fibrillation in the intensive care unit (ICU). The therapeutic goal seemed properly followed. The patient operated upon 4 months earlier was not in atrial fibrillation and took only chronic anti-platelet therapy. No valve thrombosis was observed during follow-up.
Endocarditis, re-operation and structural valve dysfunction
There were no episodes of endocarditis, nor valve reoperation or structural valve dysfunction during the first year.
Nonstructural valve dysfunction
No clinically significant haemolysis was observed in the absence of valve dysfunction. Early non-structural valve dysfunctions with mild aortic regurgitation were found in three patients. These patients were asymptomatic and remained stable at 12 months.
Haemodynamic data
The mean transvalvular gradients, effective orifice area index and left ventricular ejection fraction are described Table 3 and detailed for valve sizes 19, 21, 23, 25 and 27. Only two patients with a size 19 prosthesis were still present at 1 year. Unfortunately, only 24 (24%) patients have benefitted from data on pre-and postoperative left ventricular (LV) mass. The limited significance of these data led us not to report them.
Postoperative courses of platelet counts
All patients with thrombocytopaenia were AntiPF4 negative. Fig. 4 shows the postoperative course of the mean platelet levels for all patients undergoing aortic valve replacement isolated with FS-or SP-prostheses. Any significant differences between the two groups were detected neither preoperatively nor at the first 24 postoperative hours. The classical thrombocytopaenia observed in the immediate postoperative time (due to dilution, consumption, pulmonary sequestration and cardiopulmonary bypass (CPB) technique) was seen for every prosthetic intervention.
On the second day, we observed significant differences in platelet counts between these two groups of patients. In the FS group, the platelet decrease continues and reaches the lowest level (108.42 AE 43.2 Gpt/l), while in the SP group, the rate stabilises (138.04 AE 33.8 Gpt/l). During the second postoperative day, platelet regeneration is initiated with a gradual and steady slope in patients with FS prostheses. In the other group, this trend does not appear until the fifth day. After that, a continuous increase was observed in the two groups with a slope coefficient greater for the SP group. On the 10th day, a significant difference reappeared between the two groups.
Discussion
Stentless bioprostheses in the aortic position have been considered over stented prostheses because of their haemodynamic properties [2, 7] . The development of new stented valves has significantly reduced the haemodynamic differences between them and their stentless counterparts except for patients with small aortic annulus [8, 9] . Theoretically, the absence of a stent should provide more space available for blood flow and result in lower transvalvular gradients and larger effective orifice areas. This is especially important when one considers that calcified aortic valve stenosis with small annulus is prevalent in the older age and that septuagenarians are at higher risk of patientprosthesis mismatch. The FS bioprosthesis is a stentless pericardial valve whose stentless design and implantation technique are naturally directed to this population. We reviewed our first 100 consecutive patients with the FS bioprosthesis, and to our knowledge, this is the first intermediate-term report of this prosthesis with the largest number of patients.
The single running suture line translates into shorter mean cross-clamp times, comparable to those found by Beholz et al. [10] . It is an undeniable benefit for patients at high risk, such as those of our study. We did not find any structural valve deterioration, although Caprili et al. recently reported a very early malfunction of a large SF valve [11] . Freedom from valve-related mortality seems perfectly acceptable to patients at high risk: almost three-quarters of patients were NYHA ! 3, more than half of patients with left ventricular ejection fraction (LVEF) 45%, a logistic European Sysem for Cardiac Operative Risk Evaluation (EuroSCORE) at 12.8 AE 9.9%, a quarter of patients aged 82 years or more.
The haemodynamics of the FS bioprosthesis, in terms of transvalvular gradients and effective orifice areas indexed, have been shown to be at least as good as those of other routinely used stentless valves [2, 12, 13] . Moreover, it is interesting to note that, in our study, 24% of patients had a prosthesis size 21 or 19 and 61% a prosthesis size 23 or less. These diameters are rather lower than those reported in other studies. The FS seems to have excellent results in small aortic annulus where fear of prosthesis-patient mismatch is especially significant [14] .
In 2008, Yerebakan et al. [4] reported a significant decrease in platelet count in several cases within the early postoperative days after AVR with FS prosthesis. Several teams have subsequently observed these decreases in platelet count with varying results [15] [16] [17] . The data analysed in this study only find little differences in postoperative platelet count recovery, depending on the used aortic valve prosthesis. Indeed, platelet counts that were significantly lower were observed in the FS group at the second postoperative day (108.42 AE 43.2 vs 138.04 AE 33.8 Gpt/l). Subsequently, platelet recovery seems little altered whatever the type of prosthesis. The difference again observed on the 10th day concerns fewer patients because of the length of hospitalisation which was often shorter in our department. In conclusion, we observed slower postoperative platelet levels at 48 h and 10th postoperative day, compared to other aortic bioprosthesis during the same period. It could be a sign of higher platelet activation. However, neither suspected HIT nor postoperative bleeding or platelet substitution or thrombo-embolic events appear increased compared to our practice.
Finally, it is technically very important to take care to remove all calcium from the annulus. A too heavily calcified aortic root could impede the placement of sutures. In this case, it is preferable to avoid implanting an FS valve prosthesis. This is also true in case of excessive deformation of the aortic annulus with severe regurgitations, for example. This would cause further valve deformation and early dysfunction.
Limitations of the study
This is a single-centre experience and has the limitation of being a retrospective study. Because of the poor life expectancy of patients targeted in this study with important co-morbidities, patients at risk decrease with time independently from valve-related events and the follow-up at longer term may be more difficult.
Echocardiography was not performed by the same physician or under the same conditions.
The annual echocardiographic evaluation is more difficult to justify: the American College of Cardiology (ACC)/ American Heart Association (AHA) Guidelines for the management of patients with valvular heart disease state that routine annual echocardiograms are not indicated in the absence of a change in the clinical status in patients with a bioprosthetic valve (class III, level of evidence C) [18] .
Conclusions
The FS stentless bioprosthesis appears to be an excellent option for AVR in older and often sicker patients. Echocardiographic data showed that the haemodynamic performance, particularly in small diameters, of the FS valve is excellent and allow us to use it by first intention in this population. These results must be confirmed by long-term outcomes.
